Hill-Rom Holdings, Inc. (NYSE:HRC) – KeyCorp upped their FY2019 earnings per share estimates for shares of Hill-Rom in a report issued on Wednesday, according to Zacks Investment Research. KeyCorp analyst M. Mishan now anticipates that the medical technology company will earn $5.08 per share for the year, up from their prior forecast of $4.70. KeyCorp has a “Buy” rating and a $97.00 price objective on the stock.
Hill-Rom (NYSE:HRC) last issued its earnings results on Friday, January 26th. The medical technology company reported $0.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.13. The firm had revenue of $669.70 million for the quarter, compared to analysts’ expectations of $670.00 million. Hill-Rom had a return on equity of 20.24% and a net margin of 7.14%. The business’s revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.75 earnings per share.
Several other research analysts have also issued reports on the company. ValuEngine lowered Hill-Rom from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Zacks Investment Research lowered Hill-Rom from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Raymond James Financial upgraded Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 target price for the company in a research report on Wednesday, January 3rd. Barclays boosted their target price on Hill-Rom from $86.00 to $90.00 and gave the company an “overweight” rating in a research report on Monday, November 6th. Finally, Needham & Company LLC restated a “buy” rating on shares of Hill-Rom in a research report on Friday, January 26th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $95.38.
Hill-Rom (HRC) traded down $0.10 on Friday, reaching $79.73. The company had a trading volume of 793,812 shares, compared to its average volume of 696,664. The stock has a market capitalization of $5,276.05, a price-to-earnings ratio of 27.12, a P/E/G ratio of 1.33 and a beta of 1.05. Hill-Rom has a 12 month low of $61.28 and a 12 month high of $91.11. The company has a current ratio of 1.75, a quick ratio of 1.29 and a debt-to-equity ratio of 1.39.
In related news, SVP Paul Sherwood Johnson sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $82.99, for a total value of $82,990.00. Following the completion of the transaction, the senior vice president now owns 1,066 shares of the company’s stock, valued at $88,467.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John J. Greisch sold 125,241 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the completion of the transaction, the chief executive officer now directly owns 280,851 shares of the company’s stock, valued at approximately $23,195,484.09. The disclosure for this sale can be found here. Insiders sold 226,241 shares of company stock valued at $18,708,644 in the last quarter. 1.90% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of HRC. Seven Eight Capital LP bought a new position in Hill-Rom in the second quarter worth approximately $127,000. Citigroup Inc. raised its stake in Hill-Rom by 21.1% in the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock worth $198,000 after buying an additional 433 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in Hill-Rom by 101.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock worth $204,000 after buying an additional 1,367 shares in the last quarter. Fox Run Management L.L.C. bought a new position in Hill-Rom in the third quarter worth approximately $207,000. Finally, CAPROCK Group Inc. bought a new position in Hill-Rom in the fourth quarter worth approximately $211,000. 81.34% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2018/02/11/fy2019-earnings-estimate-for-hill-rom-holdings-inc-issued-by-keycorp-hrc.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.